Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood pressure pill tested to boost cancer drug power

NCT ID NCT05387512

Summary

This study tested if adding a common blood pressure medication (a beta-blocker) to a standard immunotherapy drug (camrelizumab) works better for controlling advanced non-small cell lung cancer. Researchers compared the two-drug combination against the immunotherapy drug alone in 59 patients. They also analyzed whether the potential benefits would be worth the cost for the healthcare system.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Department of Pharmacy, Affiliated Hospital of Nantong University

    Nantong, Jiangsu, 226000, China

Conditions

Explore the condition pages connected to this study.